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Summary: Likelihood methods for measuring statistical evidence obey the likelihood principle and
maintain excellent frequency properties. These methods lend themselves to sequential study designs
because they measure the strength of statistical evidence in accumulating data without needing
adjustments for the number of planned or unplanned examinations of data. However, sample size
projections have, to date, only been developed for fixed sample size designs. In this paper, we
consider sequential study designs for time-to-event outcomes assuming likelihood methods will be
used to monitor the strength of statistical evidence for efficacy and futility. We develop sample size
projections with the aim of controlling the probability of observing misleading evidence under the
null and alternative hypotheses, and we show how efficacy and futility considerations are managed in
this context. We also consider relaxing the requirement of specifying the simple alternative hypothesis
in advance of the study. Finally, we end with a comparative illustration of these methods in a phase
II cancer clinical trial that previously was designed within a Bayesian framework.
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Likelihood Study Designs 1
1. Introduction
When it comes to measuring the strength of statistical evidence in a given body of data,
likelihood ratios are ideally suited to the task. They do not depend on the sample space
or the prior distribution, and they retain excellent frequency properties despite strictly
adhering to the likelihood principle. Because of this, likelihood ratios are particularly useful
tools for measuring the strength of statistical evidence in sequential trials, where planned
and unplanned examinations of the data can make tail area computations cumbersome and
controversial.
In an effort to make likelihood methods more practicable, we provide likelihood based
formulae for sample size projections in sequential trials with time-to-event endpoints. Not
surprisingly, the underlying mathematical landscape is similar to that of sequential hypothe-
sis testing. However, there are subtle and important mathematical differences, e.g., likelihood
methods hold the criteria for strong evidence constant as the sample size grows instead of
holding the Type I error rate constant. Our aim is to present a comprehensive framework
for evaluating the frequency properties of likelihood sequential study designs. This includes
identifying key concepts, establishing terminology, and deriving formulae for the probabilities
of observing misleading and strong evidence, and the expected sample size in a given study
design.
The operational characteristics of likelihood study designs depend on two simple pre-
specified null and alternative hypotheses of interest. The resulting likelihood ratio, the
measure of the strength of evidence, is often criticized for its dependence on a pre-specified
simple alternative hypothesis. Although we do not agree with this criticism, we explore
what happens when the pre-specified alternative is replaced by the best supported post-hoc
alternative. As expected, the chance of being led astray does increase. However, it does not
increase as much as one might expect. Moreover, we offer a very simple design modification
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that keeps this probability to acceptable levels: forgo very early examination of the data, e.g.,
forgo sequential examination until 10% of the data are collected. The ability of likelihood
ratios to reliably accommodate post-hoc alternatives, if needed, should eliminate concerns
about pre-specifying a simple hypothesis.
We first provide a brief review of key likelihood concepts. Those familiar with likelihood
methods for measuring statistical evidence can skip this section. We then consider relaxing
the dependence of likelihood methods on a fixed simple alternative by considering post-
hoc alternatives. We then go on to consider sequential designs of time-to-event outcomes,
develop formulae for sample size projections, and discuss interim projections and futility
assessments. Finally, we illustrate these methods with a real example from a (confidential)
Phase II cancer trial of survival that was designed using Bayesian methods. Throughout this
paper the parameter of interest will be the hazard ratio comparing the experimental hazard
to the control hazard. As such, hazard ratios less than one indicate that the experimental
therapy has a smaller hazard and tends to produce longer survival times.
2. Likelihood Preliminaries
The law of likelihood explains when data represent statistical evidence for one hypothesis
over another. In particular, data better support the hypothesis that does a better job of
predicting the observed events and the likelihood ratio measures the degree to which one
hypothesis is better supported over another (Hacking, 1965; Edwards, 1972; Royall, 1997).
Introductory material on the Law of Likelihood, recent applications, and technical advances
(e.g., robustness) are available in the literature (Blume, 2002; Goodman and Royall, 2002;
Blume, 2005; Blume et. al., 2007; Blume, 2008; Strug and Hodge, 2006a,b; Royall and Tsou,
2003; Van der Tweel, 2005; Choi et. al., 2008). Sample size projections for fixed sample size
designs is discussed in Royall (1997) and Strug et. al. (2007). Various likelihood methods
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for clinical trials can be found in Piantadosi’s popular and often-cited text on clinical trials
(Piantadosi, 2005).
The law of likelihood should not be confused with the likelihood principle, which gives
the conditions under which two experiments yield equivalent statistical evidence for two
hypotheses of interest (Hacking, 1965; Birnbaum, 1962; Barnard, 1949). It follows from the
law that there are three evidential quantities: (1) a measure of the strength of evidence;
(2) the probability that a particular study design will generate misleading evidence; and (3)
the probability that observed evidence is misleading (Blume, 2008). Many of Likelihood’s
favorable attributes arise because of this distinction .
2.1 Notation and Setup
Define the log hazard ratio to be θ = ln(λt/λc) = lnψ where (λt is the hazard rate for the
treatment, λc is the hazard rate for the control group, and ψ is their hazard ratio. We will
use Cox’s Partial Likelihood (Cox, 1972, 1975) to characterize the evidence about the log
hazard ratio
L(θ) =
n∏
i=1
(
exp{θZi}∑
j∈Ri exp{θZj}
)δi
(1)
where Zi is an indicator variable for treatment, δi is a censoring indicator (zero if the i
th
subject is right censored and one otherwise), and Ri is the risk set of subjects immediately
prior to the ith event. Likelihood functions are invariant to parameter transformations, so
the evidence about θ and exp{θ} is identical.
For two competing hypotheses of interest, say H0 : θ = θ0 and H1 : θ = θ1, the strength of
the evidence for H1 over H0 is measured by LR = L(θ1)/L(θ0)
1. As the sample size grows,
the (partial) likelihood ratio will converge to either 0 or∞ in support of the true hypothesis.
1Likelihood ratios less than 8 indicate ‘weak’ evidence and likelihood ratios greater than 32 indicate ‘strong’ evidence. A
likelihood ratio of 20 is well characterized as ‘fairly strong’ or ’moderate’ evidence.
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The observed likelihood ratio will fall into one of three regions: LR ∈ [0, 1/k] indicating
strong evidence for H0 over H1, LR ∈ (1/k, k) indicating weak evidence, and LR ∈ [k,∞)
indicating strong evidence forH1 overH0. Conventional benchmarks of k = 8, 32 are points of
reference along the gradual shift from weak to moderate evidence (k = 8) and from moderate
to strong evidence (k = 32). The collection of parameter values that are best supported by
the data at the kth evidential level is called a 1/k likelihood support interval (Blume, 2002;
Royall, 1997).
2.2 Misleading Evidence
Misleading evidence is defined as strong evidence in favor of the incorrect hypothesis (e.g.,
observing LR > k when H0 is true). We never know if observed evidence is misleading or
not; all we can report is the strength of the observed evidence. As a result, it is important
to understand how often likelihood ratios can be misleading. There are a number of im-
portant results that show that the probability of observing misleading evidence is low and
controllable. We very briefly mention these results here because they will be useful in later
sections.
2.2.1 The Universal Bound. For any fixed sample size, the probability of observing mis-
leading evidence is bounded above by the inverse of the strength of evidence.
mis0 = P0
(
L(θ1)
L(θ0)
> k
)
6
1
k
(2)
where 1/k is the so-called Universal bound. This bound applies when comparing any two
hypotheses where the probability of observing the data is well defined (Pratt, 1977; Royall,
1997) and, more generally, to partial likelihoods such as (1) (Eddings, 2003; Huang, 1998).
2.2.2 The Bump Function. As the sample size grows, the probability of observing mis-
leading evidence converges to zero (i.e., mis0 → 0 as n→ ∞). This is a consequence of the
fact that a likelihood ratio will converge to either 0 or ∞ in support of the true hypothesis.
Likelihood Study Designs 5
In large samples, the probability of observing misleading evidence is virtually nonexistent
and not a concern for the experimenter. In our semi-parametric setting, a good large sample
approximation to the probability of observing misleading evidence is
mis0 ≈ Φ[− ln k/∆
√
n−∆√n/2] (3)
where ∆ is the distance between the hypotheses in expected information units, ∆ = |θ1 −
θ0|
√
I(θ0) (Eddings, 2003; Royall, 2000). This approximation is based on the asymptotic
normality of the score function and is exact, for any sample size, when the underlying model
is N(µ, σ2) so that ∆ = |µ1 − µ0|/σ. Figure 1 displays (3) under that normal model when
n = 3 (curve ‘a’) and n = 15 (curve ‘b’).
[Figure 1 about here.]
This approximation to mis0 is called the Bump function (Royall, 2000) because of its
symmetrical appearance. This function represents the probability of observing misleading
evidence for an alternative ∆ information units away from the null hypothesis on the nth
observation. A key observation is that the maximum probability of observing misleading
evidence, over all alternatives, is Φ[−√2 ln k]. When k > 8 this maximum tends to be much
less than the universal bound. The maximum is achieved at alternatives that are ±√2 ln k
standard errors from the null hypothesis.
2.2.3 The Tepee and Extended Bump Function. In a sequential trial the data are ex-
amined after each observation is collected so the Bump function no longer describes the
probability of observing misleading evidence. Specifically, the data are examined beginning
with the mth0 observation and continuing until the m
th observation. The Extended Bump
function gives the probability of observing misleading evidence between the mth0 and m
th
observation, when the data are examined after each observation in that range (Blume, 2008).
6 Biometrics, December 2010
The Extended Bump function is
P0
(
L(θ1)
L(θ0)
> k ; for any n ∈ [m0, m]
)
(4)
∼= Φ
[
−
(
ln k
∆
+ ρ
)
m−
1
2 − ∆
2
m
1
2
]
+Φ
[
−
(
ln k
∆
+ ρ
)
(m0 − 1)− 12 − ∆
2
(m0 − 1) 12
]
+
exp {−ρ∆}
k
{
Φ
[(
ln k
∆
+ ρ
)
(m0 − 1)− 12 − ∆
2
(m0 − 1) 12
]
−Φ
[(
ln k
∆
+ ρ
)
m−
1
2 − ∆
2
m
1
2
]}
where ρ is a model dependent constant that corrects the underlying continuous time approx-
imation for use in discrete time. Details can be found in (Blume, 2008) and the references
therein. This approximation works in information time (I(θ)) as opposed to participant time
(n). This approximation is very accurate when the underlying model is N(µ, σ2), in which
case we have ∆ = |µ1 − µ0|/σ and ρ = 0.583.
Settingm0 = 1 and lettingm→∞ yields an important special case. The result is the Tepee
function (Blume, 2008), which represents the maximum probability of observing misleading
evidence in a sequential study. The Tepee function is
P0
(
L(θ1)
L(θ0)
> k ; for any n = 1, 2, . . .
)
≈ exp{−ρ∆}
k
6
1
k
(5)
Assuming a normal model, figure 1 displays the Tepee function (curve ‘c’) and the Extended
Bump function (curve ‘d’) when m0 = 3 and m = 15. Note that despite an infinite number
of looks at the data (one after each observation) the probability remains bounded by the
universal bound 1/k.
The Extended Bump function provides a useful approximation to the probability of ob-
serving misleading evidence because investigators are rarely willing to stop a study very early
and funding always limits the total number of observations. The Tepee function gives the
worst case-scenario for observing misleading evidence. These scenarios mimic the behavior
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of an unscrupulous investigator who ignores all evidence not supporting his pet hypothesis
and continue to collect observations until his pet alternative is better supported over the null
hypothesis. Fortunately, the unscrupulous investigator will be thwarted at least (1−1/k)100%
of the time. Study designs that are not as biased towards the pre-specified alternative have
a smaller potential to generate misleading evidence and study designs that replace the pre-
specified alternative with a post-hoc one will have a larger potential to generate misleading
evidence.
3. Accommodating post-hoc alternatives
There is always the temptation to examine the strength of evidence for alternatives not
originally pre-specified. And because the alternative hypothesis is explicit in likelihood
methods, it is important to consider how often this activity would lead investigators astray.
As we show in the next two sub-sections, the answer is “not very often”. We find that a
price is paid for using a post-hoc alternative; the data are more likely to favor some false
alternative - as opposed to the pre-specified alternative - over a true null hypothesis. However,
this increase is negligible in fixed sample size designs, and small and manageable in practical
sequential designs.
A note on terminology: we will refer to the probability of finding some false (post-hoc)
alternative that is better supported over the true null hypothesis as the probability of being led
astray. We do this to distinguish it from the probability of observing misleading evidence,
which depends on two fixed (pre-specified) simple hypotheses and is represented by the
Bump, Tepee and Extended Bump functions.
Recall in our survival analysis example that θ is the log hazard ratio for treatment over
control. Any θ < 0 indicates that the treatment is beneficial (smaller hazard) to some
degree. Mathematically, there is strong evidence in the data supporting some alternative
(some θ < 0) over the null hypothesis (H0 : θ = 0) whenever {supθ<0 L(θ)/L(0) > k} where
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sup
θ<0
L(θ)
L(0)
=

L(θ̂)/L(0) if θ̂ < 0
1 if θ̂ > 0
(6)
where θ̂ is the MLE. For the general null hypothesis H0 : θ = θ0 we write this condition as
{supθ<θ0 L(θ)/L(θ0) > k}. The probability of being led astray is P0
(
supθ<θ0 L(θ)/L(θ0) > k
)
.
Note that we are careful to avoid interpreting supθ<0 L(θ)/L(θ0) as a evidential likelihood
ratio for the composite hypothesis Hc : θ < 0 over H0. This is because, according to the
Law of Likelihood, it is not. The generic problem is that supθ<0 L(θ) does not constitute
a properly specified probability distribution for the ‘alternative hypothesis’ (Royall, 1997;
Blume, 2002). There are a number of interesting philosophical viewpoints about this, but
we will not delve into them here. It suffices to simply use the expression supθ<0 L(θ)/L(θ0)
to indicate when there exists at least one post-hoc alternative will be better supported over
the null hypothesis.
3.1 Fixed sample size designs
In a fixed sample size design, where the examination of the data occurs only at the end of
the study, the probability of being led astray is approximately Φ[−√2 ln k] - the maximum
of the bump function. That is,
P0
(
sup
θ<θ0
L(θ)
L(θ0)
> k
)
≈ Φ[−
√
2 ln k] (7)
this approximation is exact when the underlying model is normal and holds otherwise in
moderately large samples under standard regularity conditions (see appendix). The driving
force of this result is the asymptotic normality of the score function; direct calculation yields
the result for the normal case. Because the probability of being led astray is no worse than
the maximum probability of observing misleading evidence for a fixed alternative, there
appears to be little penalty for evaluating post-hoc alternatives hypotheses in fixed sample
size designs.
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3.2 Sequential designs
We consider fully sequential designs where the data are examined beginning with the mth0
observation and continuing until the mth observation. These constraints on monitoring are
practical: m is set by the budget and m0 is often a scientific minimum need for external
validity. Because the accumulating data are examined repeatedly, the probability of being
led astray can be much higher than in a fixed sample size design. But how much higher
depends on the sample constraint ratio m/m0.
The probability of being led astray in a sequential design is bounded by
P0
(
sup
θ<θ0
L(θ)
L(θ0)
> k ; for any n ∈ [m0, m]
)
6
√
ln k
2k
√
pi
ln
(
m
m0
)
(8)
See appendix for a sketch of the proof. This bound depends on the (often very good) Brownian
motion approximation to the score function and is exact for normal models under standard
conditions. This bound is not necessarily achievable and its degree of ‘tightness’ depends on
the constraint ratio m/m0 and k. Simulation studies can be used to provide a more precise
approximation2.
When m0 = 1 and m =∞, the probability of being led astray, for any fixed k, is one (this
is a consequence of the law of the iterated logarithm). This should not be surprising; it will
always be possible to find strong evidence for some (unspecified) alternative - imaging one
infinitely close to the null hypothesis - at some point in time when we are allowed to look
forever3. But what may be surprising is that this probability is much lower for very practical
sample constraint ratios m/m0.
[Table 1 about here.]
Table 1 displays the probability observing at least k-strength evidence for some false
2We have considered only one-sided alternative hypotheses, but the results extend to two sided alternatives by doubling the
bound.
3If this were not the case, then we would only need to collect a few observations to discover the true hypothesis.
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alternative over the true null (i.e., the probability of being led astray) when examination
of the data begins after collecting the mth0 observation and continues repeatedly until the
mth observation has been collected. This is a very realistic scenario for medical research;
budget constrains set m and constraints on experimental validity often set m0. The table
shows, perhaps contrary to intuition, that the probability of being led astray is sufficiently
low and controllable through the sample constraint ratio m0/m.
An illustration is helpful. Suppose the analysis plan for a study called for repeatedly
examining the data after enrolling 10% of the maximum allowable sample size. The plan
also calls for stopping the study as soon as strong evidence for any hypothesis indicating
θ < 0 is better supported over the null hypothesis by a factor of 20 or more. Now, if the null
hypothesis is true, then by Table 1 we see that the probability of being led astray is only
0.0562. For a trial with 500 participants this amounts to 450 looks at the data, where the
alternative is left unspecified and essentially reset by the data after each observation. Yet we
will only be lead astray 5.6% of the time when the null hypothesis is true. The take home
message is that the evaluation of post-hoc alternatives hypotheses is not terribly misleading
in this context.
4. Sequential Survival Designs
In this section we detail the operational characteristics of a sequential design that uses
likelihood methods to measure the strength of evidence in the data. Recall our parameter
of interest is the log hazard ratio θ. The planned goal of our study is to generate strong
evidence for one of the two pre-specified simple hypotheses of interest, say H1 and H0, over
other under. When dealing with time-to-event endpoints the Cox partial likelihood is an
attractive option in the analysis stage, but less so for planning purposes because it lacks the
full analytical form need to yield complete projections. Therefore we consider instead two
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approaches for projecting the sample size: the first is based on the normal approximation to
the log hazard ratio and the second is based on an underlying Poisson approximation.
4.1 Projections Based on Normality Approximations
A well known normal approximation to the distribution of the log hazard ratio θ is
θ̂ ∼ N (θ, 4/d) (9)
where d is the total number of events in both groups and ψ = λt/λc = exp{θ} is the hazard
ratio. Note that if di represents the number of events in the i
th group then the variance is
1/dt +1/dc which is ≈ 4/d when dt ≈ dc and d = 2dt. This form of the variance is useful for
planning purposes when the number of events in the two groups is expected to be disparate.
Let ∆ = |θ1 − θ0|/2. If ψ1 = 0.415, then θ1 = −0.8795 and ∆ = 0.44. If ψ1 = 0.61, then
θ1 = −0.4943 and ∆ = 0.25. The sample size projections are driven by number of events
and not the number of participants. This should be clear from the variance in (9), although
θ̂ may change along with exposure time.
A slightly more accurate approximation to the expected value and variance of the log-rank
test statistic can be used to improve the projections. Using the fact that the log-rank statistic
is approximately
√
d/4 lnψ, and Freedman’s (Freedman, 1982) non-parametric formulation
for the mean and variance of the log rank statistic, we have that
θ̂ ∼ N
(
2(ψ − 1)
(ψ + 1)
,
16ψ
d(ψ + 1)2
)
(10)
To see the connection with (9) notice that 2(ψ − 1)/(ψ + 1) ≈ lnψ = θ due to a first order
power series expansion and the variance reduces to 4/D when 2
√
ψ/(ψ+1) ≈ 1. As a result,
we can see that (9) works well under the null hypothesis that ψ = 1 and less so as ψ moves
away from 1. Freedman finds that (9) is conservative when the alternative is true but not
fatally so (Freedman, 1982).
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4.2 Operational Characteristics
The trial will be stopped if there is k1-strength evidence in favor of the alternative hypothesis
H1 : θ = θ1 or k0-strength evidence in favor of the null hypothesis H0 : θ = θ0 for some
k0 < 1 < k1. That is, the trial continues as long as there is weak evidence such that k0 6
Ld(θ1)/Ld(θ0) 6 k1 where d is the total number of observed events. If Ld(θ1)/Ld(θ0) > k1,
then the trial stops for efficacy; if Ld(θ1)/Ld(θ0) < k0 then the trial stops for inefficacy (i.e.,
the null is better supported over the alternative)4.
There are two likelihood rates of misleading evidence that are analogous to the Type I
and Type II error rates of hypothesis testing: let αl = P0 (Ld(θ1)/Ld(θ0) > k1) and βl =
P1 (Ld(θ0)/Ld(θ1) > 1/k0)
5. For simplicity, we ignore any practical limits on the sample
size; we will return to this issue later. Let b = ln(k1)/∆ and a = ln(k0)/∆, so that when
k1 = 1/k0 = k we have b = −a. Remember that ∆ = |θ1 − θ0|/σ because of our normality
assumption for the log hazard ratio. Then it follows from Blume’s (Blume, 2008) likelihood
translation of Siegmund’s (Siegmund, 1985) and Wald’s (Wald, 1947) seminal works in
sequential analysis that:
αl =
1− e(a−ρ)∆
e(b+ρ)∆ − e(a−ρ)∆ 6
1− k0
k1 − k0
powerl = 1− βl =
1− e−(a−ρ)∆
e−(b+ρ)∆ − e−(a−ρ)∆ > k1
1− k0
k1 − k0 (11)
With the following expected number of events:
E0[D] =
(b+ ρ)αl + (a− ρ) (1− αl)
φ0
E1[D] =
(b+ ρ) (1− βl) + (a− ρ)βl
φ1
(12)
4Inefficacy and futility are not the same concept. Inefficacy is discovering evidence for the null hypothesis over the alternative
(e.g., the treatment does not work), while futility is the failure to generate sufficient evidence for either efficacy or inefficacy.
5This definition may appear to include weak evidence in the definition of power. However this is not the case because, for
example, 1 − βl = P1(L1/L0 > 1/8 and L1/L0 > 8) + P1(L1/L0 > 1/8 and L1/L0 < 8) and the last expression is identically
zero in a limitless sequential trial.
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where φ0 = −∆/2, φ1 = ∆/2 and ρ is a constant that accounts for the expected overshoot
of the stopping boundary in discrete time6. Wald proved that under either hypothesis, the
probability of eventually finding strong evidence in either direction is one as long as it is
possible for the sample size to be very large (Wald, 1947). Simulations (not detailed here)
indicate these approximations are accurate as long as the practical upper limit on the sample
size is in the upper quantiles of the stopping time, say 90% or 95%.
The trade-off among the evidential levels and the operating characteristics are displayed in
Tables 2 and 3 for a variety of different study designs with ∆ = 0.44, 0.25 (ψ1 = 0.415, 0.61,
these values were chosen based on our upcoming example). The centiles of the stopping
time distribution (i.e., number of events at which the study would stop) were obtained by
simulation. As the desired level of evidence increases, so too does the expected number
of events. Notice that as the the strength of evidence increases, 1 − βl increases and αl
decreases. This happens because stray or misleading sample paths have plenty of time to
correct themselves.
[Table 2 about here.]
[Table 3 about here.]
Remember that this is an approximation in information time; the number of events must be
translated into the number of participants using the relation n = d/p, where p is the expected
proportion of participants who will have the event in the study time frame. For example,
a study needing between 25 and 55 events would have to enroll between 32 (=25/0.8) and
69 (=55/0.8) participants if 80% of participants are expected to have the event during the
study follow-up period.
6Typically ρ = 0.583 for the normal distribution and ρ = 0.32 for the binomial distribution (Siegmund, 1985).
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4.3 Projections Based on Poisson Assumptions
Let di be the number of events and ti be the exposure time in the i
th group (i = t, c;
treatment or control). Here we assume dc ∼ Poiss(λctc) and dt ∼ Poiss(λttt) as in (Berry,
1983; Royall, 1997). With dc + dt = d we have the conditional distribution dt|d ∼ Bin(d, p)
where p = λttt/(λctc+λttt) = ψ/(ψ+g) with hazard ratio ψ = λt/λc = exp{θ} and exposure
ratio g = tc/tt. The conditional likelihood function for the hazard ratio, ψ, is then
L(ψ|d, g) ∝
(
ψ
ψ + g
)dt ( g
g + ψ
)dc
(13)
We can use the likelihood function’s invariance to reparameterization and base our sample
size projections on the binomial distribution7. This works because for fixed g, we have a
simple mapping from Hi : ψ = ψi to Hi : p = pi by way of pi = ψi/(ψi + g) for i = 0, 1.
If we let ∆ = ln[p1(1 − p0)/(1 − p1)p0] = ln[ψ1/ψ0] and ρ = 0.32 and φi = pi + ln[(1 −
p1)/(1− p0)]/∆, then equations (11) and (12) apply whenever p1 > p0. If p1 < p0 - as it is
in our example because 0.415 = ψ1 < ψ0 = 1 - we can reparameterize to the symmetrical
equivalent of ψ1 = 1/0.415 = 2.41, where ψ is now the hazard ratio for control to treatment.
[Table 4 about here.]
Table 6 displays the expected number of events, Ei[D], and the operating characteristics,
αl and 1− βl, using this approach. It is reassuring to see that Table 6 is in good agreement
with the projections based on the normal approximation to the log hazard given in Table
2. Note that quantiles obtained by simulation in Table 6 assume λc = 0.25. Agreement
on the frequency characteristics and expected values is to be expected when g = 1, but
agreement on stopping time quantiles is sensitive to specification of λc = 0.25
8. When g 6= 1,
the alternative formulation for the variance, 1/dt + 1/dc, should be used in (9) if the two
approaches are to agree.
7This likelihood can also be used for the analysis.
8Although our simulations and experience suggest it is not overly sensitive.
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Under this model, we can project the exposure time needed to obtain the desired number
of events, say d9, with probability at least γ, say 0.8. Assuming the ratio of exposure times
and hazards remains constant, we have D ∼ Poiss(λi) where λi = λctc(1+ψi/g) for i = 0, 1
which depends on the null and alternative hypotheses ψi. Then, with knowledge of λc, it is
a matter of numerical calculation to find the smallest tc such that
Pi(D > d) =
∞∑
j=d
e−λi(λi)
j
j!
> γ (14)
for i = 0, 1 and from tc we obtain tt = tc/g. An alternative to this numerical search would
be the following projection
tc =
Ei[D]
λc(1 + ψi/g)
(15)
for i = 0, 1, which comes from λi = Ei[D].
5. Illustration
This work was motivated by the authors’ desire to provide an alternative design to an ongoing
Phase II cancer clinical trial of a chemotherapy agent (say drug X) in participants undergoing
resection for pancreatic cancer10. Recurrence-free survival was the primary endpoint and all-
cause mortality was the secondary endpoint, so time-to-event methods were warranted. The
study was originally designed from a Bayesian perspective using data previously published
in (Oettle et. al., 2007). The simulations shown in this section use those published data on
survival rates as if they represented the true population. This provides a welcome opportunity
to assess the impact of the normality assumptions upon which our likelihood projections are
based.
9d need not be the expected value; e.g., it could be the 90% of the stopping time distribution.
10The trial is ongoing and we must maintain confidentiality regarding the active drug and the sponsor.
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5.1 Bayesian design
Previous studies yielded Kaplan-Meier estimates of disease-free survival and these data were
used to anticipate the hazard rate for the new treatment versus standard therapy: H1 :
ψ = 0.415 (∆ = 0.44). Several different survival models were considered, but the cox model
appeared to fit as well as any other model.
In the trial being designed, participants would be recruited over a 2.4 year period and
randomly assigned to the new treatment agent or standard therapy. A maximum of fifty
patients per group were to be recruited and participants could be followed for a maximum
for 4.5 years. As designed, the trial would be stopped as soon as the posterior probability
of the log hazard ratio being less than 0 was greater than 0.95 (i.e., P (θ < 0) > 0.95).
A normal skeptical prior for the log hazard ratio with mean of 0 and standard deviation of
0.5606 was used because the probability of the hazard ratio being greater than 3 was 0.02511.
The posterior distribution of the log hazard ratio would be examined as soon as 10 events
were observed and every event thereafter.
We also considered a slightly modified design where the trial would be stopped if the
posterior probability of the log hazard ratio being less than 0 was either greater than 0.95 or
less than 0.1 (i.e., not 0.1 < p(θ < 0) < 0.95). Here too, we had a maximum of fifty patients
per group and the data would not be examined until 10 events were observed.
Monte-Carlo simulation was used to determine the operational characteristics of the initial
and modified designs. Interestingly, both designs yielded the same operational characteristics
with the exception of the stopping time distribution. The probability of incorrectly stopping
the trial when the null is true (ψ = 1) was 0.132 (Type I error rate); the probability of not
stopping under the null was 0.654. Also, the probability of correctly stopping the trial when
11Likewise, the probability of hazard ratio being smaller than 1/3 was 0.025.
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the alternative was true (ψ = 0.415) was 0.96; the probability of not stopping under the
alternative was 0.038.
Increasing the cap on the sample size from 50 to 1000 did not yield any differences beyond
those in the stopping time distribution between the initial design and its modified version.
With a cap of 1000, the probability of incorrectly stopping the trial when the null is true
(ψ = 1) was 0.322 (Type I error rate); The probability of not stopping under the null was
0.134. Also, the probability of correctly stopping the trial when the alternative was true was
0.996; the probability of not stopping under the alternative was essentially 0. Clearly, the
prior is playing a noticeable role and further investigations are warranted.
5.2 Likelihood design
Table 6 shows the simulated operating characteristics of the likelihood based design. Notice
that there is an additional column on this table labeled ”non-stop” that counts the proportion
of simulations where strong evidence was not observed in either direction before resources
ran out, resulting in an inclusive study (i.e. a study that generated only weak evidence).
If the maximum number of events is increased to only 130, the resulting simulations (not
shown here) are virtually identical to the theoretical projections in table 2.
[Table 5 about here.]
To permit comparison between the operation characteristics of the Bayesian and likelihood
designs, their stopping criteria must be calibrated. This is done by noting that the Bayes
factor, equal to the posterior odds divided by the prior odds, is also a simple vs. simple
likelihood ratio under the full model with priors included. So the stopping criteria 0.1 <
p(θ < 0) < 0.95 translates to 1/9 < LR < 19 because the prior odds are one. Here the
K0 = 20 and k1 = 20 is the closest to the criterion we are looking for. The probability that
the likelihood approach ends without generating strong evidence is 0.056 under the null and
0.112 under the alternative. The comparable Type I error rate is 0.032 and power is 0.856.
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Overall, the likelihood approach fairs well when compared to the Bayesian design with
this particular prior. Note also that the likelihood design is at a slight disadvantage when
compared to the Bayesian design, because the prior that was used essentially assumes
knowledge of and additional 13 previous events (d = 4/(0.5606)2). This increase in precision
is largely responsible for the increased power with the Bayesian design and the increase in
the probability of not stopping under the null hypothesis.
5.3 Synopsis of the likelihood design
Our study has two initial hypothesis of interest: a null hypothesis that states the hazard
ratio is 1 and an alternative hypothesis that states the hazard ratio is 0.415. It is desirable
to stop the study as soon as strong evidence in favor of either hypothesis over the other is
found. The strength of the evidence in the data will be measured with a likelihood ratio and
likelihood ratios greater than 20 will indicate strong enough evidence to stop the trial.
Consider a fully sequential design where the data are examined after each observation is
collected and the study is stopped as soon as strong evidence for one of the hypotheses
(i.e., null or alternative) over the other is found. In a sequential design the sample size, or
stopping time, is random. With the aforementioned hypotheses, this design has an average
stopping time of 32 total events12 with a median stopping time of 25 events and 80th- and
95th-percentiles of 45 and 75 events13. Thus it is reasonable to plan on needing no more than
75 events. If 20% of the participants are expected to remain event free, then no more than 94
participants would be required. However, keep in mind that 50% of the time strong evidence
will be observed with less than 32 participants (32 = 25/0.8).
The operating characteristics of this fully sequential design are as follows. If the null
hypothesis is true, the probability of observing strong evidence for the alternative - misleading
12Total events is the sum of the events from both groups.
13Here the stopping time distribution is the same under the null or alternative hypothesis because the stopping strength of
evidence is the same in either direction, i.e., LR = 20.
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evidence - is only 0.037. If the alternative hypothesis is true, the probability of observing
strong evidence for the alternative is 0.96314. Thus the accumulating data can be regularly
examined for strong evidence supporting either pre-specified hypothesis over the other; the
chance of observing misleading evidence remains low.
There likely will be considerable interest in evaluating the evidence for other alternative
hypotheses that indicate the hazard ratio is less than one. If this is done at the end of the
study, then there is only a 0.72% chance of observing strong evidence for any alternative
specifying that the hazard ratio is less than one over the null hypothesis when the null
hypothesis is true (table 1). That is, there is less than 1% chance of being led astray, even
when the evidence for post-hoc alternatives hypotheses is considered at the end of the study.
Moreover, post-hoc alternatives can be considered while the trial is ongoing. Suppose the
trial is allowed to stop when strong evidence for any alternative hypothesis that indicated the
hazard ratio is less than one is better supported over the null hypothesis. If the trial cannot
collect more than 100 events and the null hypothesis is true, then we would be misled less
than 11.24% of the time. That is, the probability of observing strong evidence for any false
alternative indicating that the experimental therapy is better, when in truth the therapies are
equally good, is less than 0.112415. However, if we used a delayed sequential design that does
not allow the data to be examined until 10 events have been observed16, then the probability
of being misled drops to a reasonable 5.62% or less17. It is re-assuring that likelihood ratios
remain reliable in this setting.
14This calculation assumes a potentially infinite sample size; otherwise it is possible to end the study with only weak evidence.
However the probability of stopping with weak evidence is very small when the realistic limit on the sample size is greater than
the 95th-percentile, as is likely here.
15Simulations suggest that the actual probability is approximately 0.071.
16Determining the number of ‘run-in’ participants is not easy. One must balance the scientific and statistical gains against
the ethical imperatives to do no harm and to not engage in a demonstration trial.
17Simulations suggest that the actual probability is approximately 0.051.
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6. Remarks
Before finishing we would like to point out the flexibility of this approach for interim projec-
tions and futility assessments. During the course of a trial it can be helpful to compute the
conditional probability that the trial will eventually yield strong evidence for the alternative
or null hypothesis given the observed evidence collected so far. Futility is a consideration
here, as the degree to which the interim results will change, if the trial is allowed to continue,
will influence the decision to continue the trial.
With likelihood methods the calculation of these conditional probabilities, or interim
projections, is straightforward. Let LRint be the likelihood ratio at the interim analysis,
LRaft be the likelihood ratio from the data collected after the interim analysis, and let
LRfin be the final end-of-study likelihood ratio. Clearly, LRint ∗ LRaft = LRfin. Then
Pi[LRfin > k|LRint = kint] = Pi[LRaft > k/kint] (16)
where i = 0, 1 and kint is the observed strength of evidence at the interim analysis. So,
for example, after observing a likelihood ratio of 10 in an interim analysis with only 50
participants out of the planned 100, the probability of observing a final likelihood ratio
greater than 32 is just Pi(LR > 3.2 in 50 participants) for i = 1, 0. Equations (3), (5),
and (11) are then used to perform the desired calculations assuming a maximum of 50
participants.
In summary, we have shown that despite their lack of adjustment for multiple looks at
the data likelihood ratios remain reliable measures of the strength of statistical evidence. In
addition, while specification of a simple alternative hypothesis is important for determining
the operational characteristics of the study design, post-hoc alternatives can be reliably
examined at the conclusion of the study and even during the study if the study is designed
appropriately (i.e., the data are not examined very early on). Likelihood methods for measur-
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ing statistical evidence have a number of positive attributes and good frequency properties
in sequential studies is yet another.
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Appendix Sketch of Proofs
Result (7):
P0
(
sup
θ<θ0
L(θ)
L(θ0)
> k
)
≈ Φ[−
√
2 ln k]
Under a normal model, X1, . . . , Xn ∼ N(θ, σ2), direction calculation shows this relationship
to be exact. Also, note that P0 (supθ L(θ)/L(θ0) > k) = 2Φ[−
√
2 ln k]. If X1, . . . , Xn ∼
f(Xi, θ) where f is a smooth function of the real-values parameter θ, then
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lim
n→∞
P0
(
sup
θ
L(θ)
L(θ0)
> k
)
= 2Φ[−
√
2 ln k]
To see this, write down the Taylor expanded difference of the log-likelihoods at the MLE
around the true value θ0 and write down the score equation. Use the score equation to solve
for (θˆ−θ0) and plug this solution into the Taylor expanded difference of log-likelihoods. This
yields
ln(θˆ)− ln(θ0) = −
[
∂ln(θ)
∂θ
|θ0
]2
/2
[
∂2ln(θ)
∂θ2
|θ0
]
+R
Now R = Op(n
−1/2) under mild conditions and (1/
√
n)∂ln(θ)/∂θ|θ0 d−→ N (0, I(θ0)) and
(1/n)∂2ln(θ)/∂θ
2|θ0 p−→ −I(θ0). Thus we have
ln(θˆ)− ln(θ0) d−→ |Z| where Z ∼ N(0, 1)
and the result follows.
Result (8):
P0
(
sup
θ<θ0
L(θ)
L(θ0)
> k ; for any n ∈ [m0, m]
)
6
√
ln k
2k
√
pi
ln
(
m
m0
)
Let X1, . . . , Xn ∼ N(θ, σ2) and without loss of generality let θ0 = 0, σ = 1. We use a device
and result from Lorden (1973). Notice that
P0
(
sup
θ<θ1
L(θ)
L(θ0)
> k ; for any n ∈ [m0, m]
)
= P0
(
m0 6 N1 <
2 ln k
∆2
)
+ P0
(
2 ln k
∆2
6 N2 6 m
)
where ∆ = |θ1 − θ0| and stopping time N1 = inf
{
n : 1 6 n < 2 lnk
∆2
, Sn >
√
2 ln k
√
n
}
or ∞
if no such n exists, and stopping time N2 = inf
{
n : 2 lnk
∆2
6 n, Sn >
[
ln k
∆
+ n∆
2
]}
or ∞ if no
such n exists. The condition in N1 requires that ∆ <
√
2 ln k/n, but in our case ∆ = 0
so this condition is always met. Therefore, P0
(
supθ<θ0
L(θ)
L(θ0)
> k ; for any n ∈ [m0, m]
)
=
P0
(
m0 6 N1 < min(m,
2 lnk
∆2
)
)
which can be bounded by
∫m
m0
(
√
ln k/t2k
√
pi)dt Lorden (1973)
and this yields the result.
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Figure 1. The Bump, Extended Bump, and Tepee functions
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Table 1
Bounds on the probability of being led astray for designs with continual examination of data
after 1%, 5%, 10%, 20%, 50%, and 100% of the data have been collected. A sample
constraint ratio of 1 is a fixed sample size design. Equation (8) was used to produce this
table with the exception of the last column for which equation (7) was used.
Strength of Sample Constraint Ratio (m0/m)
Evidence 0.01 0.05 0.1 0.2 0.5 1
8 0.2342 0.1523 0.1171 0.0818 0.0352 0.0207
20 0.1124 0.0731 0.0562 0.0393 0.0169 0.0072
32 0.0756 0.0492 0.0378 0.0264 0.0114 0.0042
64 0.0414 0.0269 0.0207 0.0145 0.0062 0.0020
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Table 2
Likelihood study design with H1 : ψ = 0.415 (∆ = 0.44)
Evidence Oper. Char. Distribution of stopping times (events)
k0 k1 E[D] 25% 50% 75% 80% 90% 95%
Null αl = 0.088 20 10 16 25 29 40 49
1/8 8
Alt 1− βl = 0.912 20 10 16 26 29 39 50
Null αl = 0.036 25 11 19 32 36 48 61
1/10 20
Alt 1− βl = 0.925 30 15 24 38 42 56 69
Null αl = 0.037 32 16 25 41 45 61 75
1/20 20
Alt 1− βl = 0.963 32 16 25 40 44 58 74
Null αl = 0.023 32 16 26 41 47 62 78
1/20 32
Alt 1− βl = 0.962 36 19 30 46 51 67 82
Null αl = 0.024 37 20 30 47 53 70 87
1/32 32
Alt 1− βl = 0.976 37 20 30 48 52 69 86
Null αl = 0.012 38 20 30 48 54 71 88
1/32 64
Alt 1− βl = 0.976 44 24 37 56 61 80 99
Null αl = 0.012 45 25 38 57 63 82 100
1/64 64
Alt 1− βl = 0.988 45 25 37 57 63 81 101
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Table 3
Likelihood study design with H1 : ψ = 0.61 (∆ = 0.25)
Evidence Oper. Char. Events
k0 k1 E[D] 25% 50% 75%
Null αl = 0.098 58 28 46 76
1/8 8
Alt 1− βl = 0.903 58 27 44 74
Null αl = 0.040 72 33 54 93
1/10 20
Alt 1− βl = 0.917 86 44 71 111
Null αl = 0.041 93 46 74 119
1/20 20
Alt 1− βl = 0.959 93 46 74 119
Null αl = 0.026 95 47 76 125
1/20 32
Alt 1− βl = 0.958 107 57 88 137
Null αl = 0.026 110 57 89 141
1/32 32
Alt 1− βl = 0.974 110 57 89 141
Null αl = 0.013 113 57 90 142
1/32 64
Alt 1− βl = 0.973 131 72 108 166
Null αl = 0.013 135 74 112 171
1/64 64
Alt 1− βl = 0.987 135 74 111 168
Likelihood Study Designs 29
Table 4
Likelihood study design with H1 : ψ = 2.41 and g = 1; Quantiles obtained by simulation
assume λc = 0.25.
Evidence Oper. Char. Distribution of stopping times (events)
k0 k1 E[D] 25% 50% 75% 80% 90% 95%
Null αl = 0.086 21 9 16 27 31 41 51
1/8 8
Alt 1− βl = 0.914 23 12 18 29 32 42 54
Null αl = 0.035 26 11 20 33 38 51 64
1/10 20
Alt 1− βl = 0.927 33 18 27 41 45 57 72
Null αl = 0.036 33 16 26 42 47 62 77
1/20 20
Alt 1− βl = 0.964 35 19 28 45 50 65 80
Null αl = 0.023 34 16 26 42 47 65 80
1/20 32
Alt 1− βl = 0.963 40 22 33 49 54 72 89
Null αl = 0.023 39 20 30 48 55 71 89
1/32 32
Alt 1− βl = 0.977 41 23 33 51 56 74 92
Null αl = 0.012 39 20 32 50 56 73 93
1/32 64
Alt 1− βl = 0.977 49 28 40 61 66 86 104
Null αl = 0.012 47 25 38 58 64 84 102
1/64 64
Alt 1− βl = 0.988 50 28 40 62 68 86 104
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Table 5
Simulation results for likelihood study design in illustrative example with H1 : ψ = 0.415
(∆ = 0.44). The data were sequentially examined upon observing each event after a total of
10 events were observed. The maximum number of subjects per group was assumed to be 50.
Evidence Oper. Char. Non-stop Distribution of stopping times (events)
k0 k1 E[D] 25% 50% 75% 80% 90% 95% 100%
Null αl = 0.094 0.004 25 14 20 30 35 46 58 80
1/8 8
Alt 1− βl = 0.892 0.026 23 13 17 29 32 40 53 71
Null αl = 0.032 0.056 36 20 29 45 52 67 75 87
1/20 20
Alt 1− βl = 0.856 0.112 33 20 29 42 47 58 62 71
Null αl = 0.016 0.096 40 23 34 53 60 72 77 87
1/32 32
Alt 1− βl = 0.824 0.148 37 25 34 49 52 61 64 71
Null αl = 0.004 0.138 45 27 40 63 68 76 78 87
1/64 64
Alt 1− βl = 0.758 0.224 43 31 41 55 58 62 65 71
